P428: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysisECCO'22Year: 2022
Authors: Lightner, A.(1);Ream, J.(2);Nachand, D.(2);Fulmer, C.(3);Regueiro, M.(4);Steele, S.(5);
(1)Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Radiology, Cleveland OH, United States;(3)Cleveland Clinic, Pathology, Cleveland OH, United States;(4)Cleveland Clinic, Gastroenterology, Cleveland OH, United States;(5)Cleveland Clinic, Colorectal Surgery, Cleveland OH, United States;
P430: Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort studyECCO'22Year: 2022
Authors: Honap, S.(1,2);Sharma, E.(1);Ray, S.(1);Mawdsley, J.(1);Anderson, S.(1);Samaan, M.(1);Pavlidis, P.(1,2);Irving, P.(1,2);
(1)Guy’s and St Thomas’ NHS Foundation Trust, IBD Centre - Department of Gastroenterology, London, United Kingdom;(2)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;
P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trialECCO'22Year: 2022
Authors: Reinisch, W.(1);Axelrad, J.(2);Ahmad, H.A.(3);Pondel, M.(3);Ather, S.(3);Elegbe, A.(3);Sninsky, C.(4);Longman, R.(5);
(1)Medical University of Vienna, Gastroenterology, Vienna, Austria;(2)NYU Langone, Gastroenterology, New York, United States;(3)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(4)Digestive Disease Associates, Tbc, Gainesville, United States;(5)Weill Cornell Medicine, Tbc, New York, United States;
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.ECCO'22Year: 2022
Authors: Garcia-Alvarado, M.(1);Barrio, J.(2);Sierra-Ausin, M.(3);Arias, L.(4);Fernández-Salazar, L.(5);Fuentes Coronel, A.(6);Arias García, L.(7);García-Alonso, F.J.(8);García-Prada, M.(3);Legido, J.(4);Sánchez-Hernández, J.G.(9);Muñoz, F.(10);
(1)University Hospital Salamanca, Gastroenterology, Salamanca, Spain;(2)Hospital Universitareio Río Hortega, Gastroenterology, Valladolid, Spain;(3)Hospital Universitario de León, Gastroenterology, León, Spain;(4)Complejo Asistencial de Segovia, Gastroenterology, Segovia, Spain;(5)Hospital Clínico Universitario de Valladolid, Gastroenterology, Valladolid, Spain;(6)Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain;(7)Hospital Universitario de Burgos, Gastroenterology, Gastroenterology, Spain;(8)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(9)Hospital Universitario de Salamanca, Pharmacy Service, Salamanca, Spain;(10)Hospital Universitario de Salamanca, Gastroetnerology, Salamanca, Spain;GEICYL (Group of Inflammatory Bowel Disease of Castilla y León)
P434: The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Dignass, A.U.(1);Gisbert, J.P.(2);Bossa, F.(3);Freudensprung, U.(4);Addison, J.(5);
(1)Agaplesion Markus Hospital- Goethe University, Department of Medicine, Frankfurt, Germany;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad Autónoma de Madrid, Gastroenterology Unit, Madrid, Spain;(3)Fondazione Casa Sollievo della Sofferenza – IRCCS - San Giovanni Rotondo, Division of Gastroenterology, Puglia, Italy;(4)Biogen International GmbH, Global Head of Medical Data Science and Analytics MDSA Biosimilars, Baar, Switzerland;(5)Biogen Biosimilars Unit, Medical, Baar, Switzerland;
P435: High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohortECCO'22Year: 2022
Authors: Elial-Fatal, S.(1);Pfeffer-Gik, T.(1,2);Raykhel, B.(1);Friedenberg, A.(1);Margolis, L.(1);Barkan, R.(1);Ollech, J.(1,2);Yanai, H.(1,2);Wasserberg, N.(2,3);White, I.(2,3);Dotan, I.(1,2);Godny, L.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah-Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Rabin Medical Center, Division of Surgery- Colorectal Unit, Petah-Tikva, Israel;
P436: Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)ECCO'22Year: 2022
Authors: Dipasquale, V.(1);Pellegrino, S.(1);Cucinotta, U.(1);Citrano, M.(2);Graziano, F.(2);Cappello, M.(3);Busacca, A.(3);Orlando, A.(4);Accomando, S.(5);Romano, C.(1);
(1)University of Messina Hospital G. Martino, Department of Human Pathology in Adulthood and Childhood @G. Barresi@, Messina, Italy;(2)Pediatric Unit- Villa Sofia Cervello Hospital, Pediatric, Palermo, Italy;(3)Gastroenterology and Hepatology Section- Internal Medicine and Medical Specialties PROMISE- University of Palermo, Department of Health Promotion- Mother and Child Care, Palermo, Italy;(4)IBD Unit- Villa Sofia Cervello Hospital, Department of Medicine, Palermo, Italy;(5)G di Cristina Children's Hospital- University of Palermo, Pediatric Department, Palermo, Italy;Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.ECCO'22Year: 2022
Authors: Risto, A.(1);Andersson, R.E.(1);Landerholm, K.(1);Bengtsson, J.(2);Block, M.(2);Myrelid, P.(1);
(1)Linkoping University, Department of Biomedical and Clinical Sciences- Faculty of Health Sciences- Linköping University- Linköping- Sweden., Linköping, Sweden;(2)Sahlgrenska University Hospital, Department of surgery- colorectal unit., Gothenburg, Sweden;
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.ECCO'22Year: 2022
Authors: Roblin, X.(1);Bastide, L.(1);veyrard, P.(1);berger, A.E.(2);Paul, S.(2);
(1)CHU Saint Etienne - Hospital Nord, Department of Gastroenterology and Hepatology- Inserm- CIC1408, Saint Priest en Jarez, France;(2)CHU Saint Etienne - Hospital Nord, Immunology- Inserm- CIC1408, Saint Priest en Jarez, France;
P440: Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.ECCO'22Year: 2022
Authors: Savelkoul, E.(1);Thomas, P.(1);Derikx, L.(1);Den Broeder, N.(1);Römkens, T.(2);Hoentjen, F.(3);
(1)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Jeroen Bosch Hospital- 's-Hertogenbosch, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(3)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;
P441: Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.ECCO'22Year: 2022
Authors: Moens, A.(1);Verstockt, B.(1);Alsoud, D.(2);Sabino, J.(1);Ferrante, M.(1);Vermeire, S.(1);
(1)University Hospitals Leuven, Department of gastroenterology and Hepatology, Leuven, Belgium;(2)Catholic University Leuven, Department of chronic diseases- metabolism and aging, Leuven, Belgium;
P442: Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative ColitisECCO'22Year: 2022
Authors: Alsoud, D.(1);Compernolle, G.(2);Tops, S.(2);Sabino, J.(1,3);Ferrante, M.(1,3);Thomas, D.(2);De Hertogh, G.(4);Vermeire, S.(1,3);Verstockt , B.(1,3);
(1)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism and Ageing, Leuven, Belgium;(2)KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies- Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Hospitals Leuven, Laboratory of Morphology and Molecular Pathology, Leuven, Belgium;
P444: COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohortECCO'22Year: 2022
Authors: Farkas, K.(1);Matuz, M.(2);Kata, D.(3);Földesi, I.(3);Resál, T.(1);Bacsur, P.(1);Szántó, K.(1);Kolarovszki-Erdei, D.(1);Rutka, M.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Sarlós, P.(4);Miheller, P.(5);Zacháry, A.(6);Molnár, T.(1);
(1)University of Szeged, Department of Medicine- Szent-Györgyi Albert Medical School, Szeged, Hungary;(2)University of Szeged, Department of Clinical Pharmacy- Faculty of Pharmacy- University of Szeged- Szeged- Hungary, Szeged, Hungary;(3)University of Szeged, Department of Laboratory Medicine, Szeged, Hungary;(4)University of Pécs, Gastroenterology Unit- 1st Department of Medicine, Pécs, Hungary;(5)Semmelweis University, Department of Surgery and Interventional Gastroenterology, Budapest, Hungary;(6)Hungarian Association of Crohn's Colitis, Hungarian Association of Crohn's Colitis, Budapest, Hungary;
P445: Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from HungaryECCO'22Year: 2022
Authors: Lontai, L.(1);Gonczi, L.(1);Komlodi, N.(1);Balogh, F.(1);Barkai, L.(1);Ilias, A.(1);LakatosPhD, P.L.(1,2);
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)Mcgill University Health Center, IBD Centre, Montréal, Canada;
